Cite
HARVARD Citation
Hou, M. et al. (n.d.). 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC). Journal for immunotherapy of cancer. pp. A47-A48. [Online].